Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 11/20 | 0.36 |
| ▸ | CA2 | P00918 | 10/20 | 0.36 |
| ▸ | CA12 | O43570 | 8/20 | 0.36 |
| ▸ | CA9 | Q16790 | 7/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21871858 | 0.81 | MEN1 (0.51) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4114478 | 0.76 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23905245 | 0.74 | TDP1 (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL22535992 | 0.71 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23744212 | 0.71 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23643797 | 0.70 | MEN1 (0.50) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5052626 | 0.70 | TDP1 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL25796713 | 0.70 | TDP1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL15612944 | 0.69 | TDP1 (0.55) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL2523550 | 0.69 | TDP1 (0.55) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, MYD88 | MEN1 1377/4885GAA 667/4885KMT2A 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.